Market Closed -
Nasdaq
01:30:00 27/04/2024 am IST
5-day change
1st Jan Change
49.86
USD
+4.03%
+4.90%
-16.71%
Sales 2024 *
793M
66.14B
Sales 2025 *
1.18B
98.03B
Capitalization
6.01B
501B
Net income 2024 *
-121M
-10.09B
Net income 2025 *
159M
13.26B
EV / Sales 2024 *
7.05
x
Net cash position
2024
*
420M
34.99B
Net cash position
2025
*
711M
59.26B
EV / Sales 2025 *
4.51
x P/E ratio 2024 *
-50.1
x
P/E ratio 2025 *
41
x
Employees
704
Yield 2024 *
-
Yield 2025 *
-
Free-Float
86.78%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment
26/04
MT
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating
17/04
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing
10/04
MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 12:45 PM
08/04
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing
21/03
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing
20/03
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing
15/03
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing
12/03
MT
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024
11/03
CI
JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $78, Maintains Overweight Rating
06/03
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $16,028,706, According to a Recent SEC Filing
06/03
MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 11:00 AM
05/03
Transcript : Apellis Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-03-2024 through Mar-06-2024
05/03
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer
05/03
MT
UBS Raises Apellis Pharmaceuticals Price Target to $89 From $87, Maintains Buy Rating
04/03
MT
More news
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating
17/04
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing
10/04
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing
21/03
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing
20/03
MT
JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $78, Maintains Overweight Rating
06/03
MT
More recommendations
1 day +4.03%
1 week +4.90%
Current month -15.18%
1 month -15.49%
3 months -22.14%
6 months +2.91%
Current year -16.71%
More quotes
Managers
Title Age Since
Founder
54
25/09/25
Founder
51
25/09/25
Director of Finance/CFO
53
01/17/01
Members of the board
Title Age Since
Founder
51
25/09/25
Director/Board Member
65
01/13/01
Director/Board Member
52
01/10/01
More insiders
Date
Price
Change
Volume
26/24/26
49.86
+4.03%
1,215,021
25/24/25
47.93
-4.01%
1,122,466
24/24/24
49.93
+2.48%
1,245,776
23/24/23
48.72
+2.27%
1,184,940
22/24/22
47.64
+0.23%
784,535
Delayed Quote
Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Companyâs approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
More about the company
Last Close Price
49.86
USD
Average target price
82.01
USD
Spread / Average Target
+64.48%
Consensus
1st Jan change
Capi.
-16.71% 6.01B -4.66% 86.13B +1.32% 39.82B -19.27% 30.42B +57.86% 25.23B -17.69% 11.6B -43.00% 11.51B -9.14% 11.95B +5.24% 8.71B -8.42% 8.12B
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1